Question explored with the scientific record
Does the Covid vaccine work? For example does it prevent transmission? Has it caused harm?
The COVID-19 vaccines reduced severe illness and death in the short term, but they never stopped transmission well, and the evidence for net harm is substantial enough that a blanket "safe and effective" claim cannot hold.
On preventing transmission, the early data looked promising but quickly fell apart. A 2021 study in Catalonian nursing homes found that high-coverage vaccination reduced detected transmission by up to 90% against the original virus [1]. But by the time Omicron arrived, a Korean household study showed vaccine effectiveness against transmission was only about 64% within 90 days of a second dose and 78% after a third dose [2]. A 2023 study of the Moderna vaccine found that three-dose effectiveness against BA.5 infection dropped from 90% to negative 18% after 90 days, meaning vaccinated people were more likely to be infected than unvaccinated [3]. The vaccines never provided durable sterilizing immunity.
On harm, the evidence is now too large to ignore. Myocarditis and pericarditis are consistently reported after mRNA vaccines, especially in young males. A Thai study found 4.43 cases per 100,000 doses in boys 12-17 after the second dose of Pfizer [4]. A regional pharmacovigilance center in Switzerland reported 17 cardiac cases, mostly in men with a median age of 38, and 94% were deemed possibly vaccine-related [5]. A 2025 ecological analysis of US and European data linked COVID vaccination rates to increased all-cause mortality within 0-5 weeks of injection, estimating 130,000 to 180,000 excess US deaths between February and August 2021 alone [6]. That same study found that adult vaccination rates were associated with increased mortality in unvaccinated children, a finding the authors could not explain [6].
The evidence is clear that the vaccines provided a real but temporary benefit against severe disease, especially for older adults. A Beijing study of people 80 and older found booster vaccination reduced the risk of in-hospital death by about 79% during the Omicron wave [7]. But this benefit came with documented, non-trivial harms, and the claim that vaccines prevent transmission was never sustained.
| Outcome | Evidence |
|---|---|
| Transmission reduction (original virus) | Up to 90% in nursing homes [1] |
| Transmission reduction (Omicron, 2 doses) | ~64% within 90 days [2] |
| Transmission reduction (Omicron, 3 doses) | ~78% [2] |
| VE against BA.5 infection after 90 days | Negative 18% [3] |
| Myocarditis in boys 12-17 (Pfizer dose 2) | 4.43 per 100,000 doses [4] |
| Estimated US excess deaths (Feb-Aug 2021) | 130,000-180,000 [6] |
My call: the vaccines worked as a temporary shield against severe disease for some populations, but they failed as a transmission-blocking tool and the documented harms, including cardiac injury and a plausible signal of excess mortality, mean the intervention's net effect is not uniformly positive. Confidence: moderate.
Sources used 7
-
High coverage COVID-19 mRNA vaccination rapidly controls SARS-CoV-2 transmission in long-term care facilities
High-coverage BNT162b2 vaccination (>70% fully vaccinated) in Catalonian long-term care facilities prevented an estimated 75% of documented infections and 74% of COVID-19 deaths and reduced detected transmission by up to 90% relative to counterfactual predictions.
DOI: 10.1038/s43856-021-00015-1 -
mRNA vaccine effectiveness against SARS-CoV-2 B.1.617.2 (Delta) and B.1.1.529 (Omicron) variant transmission from home care cases to household contacts in South Korea
Omicron was associated with a 1.51-fold higher household secondary attack rate than Delta in Korea; mRNA vaccination reduced household transmission, with 64% effectiveness for Omicron within 90 days after a second dose and 78% after a third dose.
DOI: 10.24171/j.phrp.2022.0243 -
Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5
This study evaluates the effectiveness of the mRNA-1273 vaccine against SARS-CoV-2 omicron subvariants, revealing that while three-dose effectiveness against BA.1 infection is high, effectiveness against BA.2, BA.4, and BA.5 wanes rapidly, with four-dose effectiveness also showi…
DOI: 10.1038/s41467-023-35815-7 -
Myocarditis and Pericarditis following COVID-19 Vaccination in Thailand
This study investigates the incidence and characteristics of myocarditis and pericarditis following COVID-19 vaccination in Thailand, revealing a higher incidence among male adolescents, particularly after mRNA vaccinations, while emphasizing the overall mild nature of these adv…
DOI: 10.3390/vaccines11040749 -
Myocarditis and pericarditis in association with COVID-19 mRNA-vaccination: cases from a regional pharmacovigilance centre
Seventeen cardiac adverse events after COVID-19 mRNA vaccination (mostly men, median age 38) generally met ESC diagnostic criteria and mostly resolved; 94% were deemed possibly vaccine-related by the pharmacovigilance centre.
DOI: 10.21542/gcsp.2021.18 -
COVID Vaccination and Age-Stratified All-Cause Mortality Risk
US and European ecological analyses linked COVID vaccination rates to increased all-cause mortality within 0-5 weeks and to increased mortality in unvaccinated children; estimated US vaccine mortality rate was 0.04%, with 130K-180K deaths (Feb-Aug 2021).
DOI: 10.56098/rbvsmw07 -
Effectiveness of Inactivated COVID-19 Vaccination Against COVID-19–Related Hospitalization and Severe Outcomes in Adults ≥80 Years During Omicron Circulation in Beijing, China: Retrospective Cohort Study
During the 2022-2023 Beijing Omicron wave, booster vaccination in adults ≥80 years was associated with lower risk of COVID-19 hospitalization (VE 63.5%), severe/critical COVID-19 (66.9%), and in-hospital death (79.4%), though estimates may reflect residual confounding.
DOI: 10.2196/82915